What is the dosage and administration of heparin for the prevention and treatment of thromboembolic disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Heparin Dosage and Administration for Thromboembolic Disorders

For prevention and treatment of thromboembolic disorders, heparin should be administered as follows: for prophylaxis, 5000 U subcutaneously every 8-12 hours; for treatment, 5000 U IV bolus followed by 32,000 U per 24 hours by continuous IV infusion, adjusted to maintain aPTT at 1.5-2.5 times control value. 1

Prophylactic Dosing

Low-Risk Patients

  • Dosage: 5000 U subcutaneously every 8-12 hours 1
  • Duration: Continue for 7 days or until patient is fully ambulatory, whichever is longer 2
  • Administration: Use deep subcutaneous injection with a fine (25-26 gauge) needle to minimize tissue trauma 2

High-Risk Patients (e.g., total hip replacement)

  • Dosage: Subcutaneous heparin every 12 hours, adjusted to prolong aPTT by 4-5 seconds into upper normal range 3
  • Monitoring: Regular platelet count monitoring is recommended for early detection of heparin-induced thrombocytopenia 1

Treatment Dosing

Venous Thromboembolism

  • Initial dose: 5000 U IV bolus 1
  • Maintenance: 32,000 U per 24 hours by continuous IV infusion 1
  • Alternative: 35,000-40,000 U per 24 hours subcutaneously 1
  • Target: Adjust dose to maintain aPTT at 1.5-2.5 times control value 1, 3
  • Duration: 5-day course is as effective as 10-day course 1

Coronary Heart Disease

  • Unstable angina or acute MI without thrombolytic therapy:

    • Initial: 5000 U IV bolus
    • Maintenance: 32,000 U per 24 hours by IV infusion
    • Target: Maintain aPTT in therapeutic range 1
  • Acute MI after thrombolytic therapy:

    • Initial: 5000 U IV bolus
    • Maintenance: 24,000 U per 24 hours
    • Target: Maintain aPTT in therapeutic range 1

Endovascular Procedures

  • Pre-procedure: Consider aspirin with ticlopidine or clopidogrel for 3 days before procedure 4
  • During procedure: Initial IV bolus of 100 units/kg followed by supplemental doses to maintain ACT between 300-350 seconds 4
  • Post-procedure: For patients with complications (dissections, mural thrombosis, or new neurological symptoms), continue heparin to maintain aPTT at 1.5-2.3 times control values for 24 hours 1

Pediatric Dosing

  • Initial dose: 75-100 units/kg IV bolus over 10 minutes 2
  • Maintenance:
    • Infants: 25-30 units/kg/hour (infants <2 months have highest requirements, averaging 28 units/kg/hour)
    • Children >1 year: 18-20 units/kg/hour
    • Older children: May require less heparin, similar to weight-adjusted adult dosage 2
  • Target: Adjust to maintain aPTT of 60-85 seconds 2

Monitoring

  • Initial testing: Baseline coagulation status (aPTT, INR, platelet count) 2
  • Continuous IV infusion: Check aPTT approximately every 4 hours initially, then at appropriate intervals 2
  • Intermittent IV injection: Perform coagulation tests before each injection during initiation 2
  • Subcutaneous administration: Test 4-6 hours after injection 2
  • Ongoing monitoring: Periodically monitor platelet counts, hematocrit, and occult blood in stool throughout therapy 2

Alternative Options

  • Low molecular weight heparin (LMWH): Enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily has shown equivalent efficacy to unfractionated heparin for venous thromboembolism 5

Special Considerations

  • Heparin-induced thrombocytopenia (HIT): For patients with risk >1%, monitor platelet count every 2-3 days from day 4 to day 14 1
  • Cardiovascular surgery: Initial dose of at least 150 units/kg; often 300 units/kg for procedures <60 minutes or 400 units/kg for procedures >60 minutes 2
  • Converting to warfarin: Continue full heparin therapy until INR reaches stable therapeutic range 2

Pitfalls and Caveats

  • Intramural thrombosis can occur in >90% of deeply injured arteries even with ACT elevated to 4-5 times control 1
  • Avoid using heparin as a "catheter lock flush" product to prevent fatal medication errors 2
  • Use different injection sites for subcutaneous administration to prevent hematoma development 2
  • Use preservative-free heparin in neonates and infants 2
  • Regular monitoring is essential as heparin has marked intra- and inter-patient variability in anticoagulant response 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antithrombotic Therapy for Arterial Dissection Flaps

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Old and new heparins.

Thrombosis research, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.